OR WAIT null SECS
April 22, 2008
Also, GSK expands in Ireland, executive appointments at ProGenTech, more...
April 16, 2008
Also, Alcon plans to open Singapore facility, Pharmacopeia president and CEO retired, more...
April 10, 2008
Also, Jubilant Organosys to acquire DRAXIS Health, PPD's Paul Covington to retire, more...
April 03, 2008
Also, VaxGen and Raven terminate merger agreement, Darren Head appointed CEO of Cytovance, more...
April 02, 2008
The former formulation-development business of MDS Pharma Services seeks to build its niche in early-phase drug development.
The FDA itself issues a cry for help. Is anybody listening?
April 01, 2008
The blood–brain barrier (BBB) forms an interface between the circulating blood and the brain, and functions as a tremendously effective barrier for the delivery of potential neurotherapeutics into the brain parenchyma. Conversely, the BBB possesses various carrier-mediated transport systems for the uptake of small molecules, such as essential nutrients and vitamins. These transporters have become an attractive target for drug/prodrug design in an attempt to ferry drug molecules across the BBB. Central nervous system (CNS) drug delivery is often limited by poor brain penetration of the potential drug candidate. As a result of its unique barrier properties, the BBB poses a huge challenge for the delivery of potential neurotherapeutics into the brain parenchyma.1 It is estimated that only 2% of small-molecule drugs and ,0.1% of novel protein and peptide pharmaceuticals developed for CNS diseases reach therapeutic concentrations in the brain.2,3 Many of the pharmacologically active drugs tend to fail..
Our company is involved in developing and manufacturing APIs that can be utilized with drug-eluting stents (DES). Despite ensuring constancy in pharmaceutical composition, we are experiencing issues with variations in drug release during in vitro studies. We are working closely with a stent manufacturer to develop the system, but could surface analysis techniques investigate the problem further?
Spraying techniques can be used to produce powder form formulations. The concept works by the adsorption/absorption of a liquid SELF onto a neutral carrier…
Liquid and semisolid encapsulation using two-piece hard capsules is an ideal drug delivery approach for highly potent compounds and poorly water-soluble drugs. The authors detail the factors to reduce risk when designing and operating a facility for secondary manufacturing of highly potent drugs.